Literature DB >> 19747834

Thienylhalomethylketones: Irreversible glycogen synthase kinase 3 inhibitors as useful pharmacological tools.

Daniel I Perez1, Santiago Conde, Concepción Pérez, Carmen Gil, Diana Simon, Francisco Wandosell, Francisco J Moreno, José L Gelpí, Francisco J Luque, Ana Martínez.   

Abstract

Thienylhalomethylketones, whose chemical, biological, and pharmaceutical data are here reported, are the first irreversible inhibitors of GSK-3beta described to date. Their inhibitory activity is likely related to the cysteine residue present in the ATP-binding site, which is proposed as a relevant residue for modulation of GSK-3 activity. The good cell permeability of the compounds allows them to be used in different cell models. Overall, the results presented here support the potential use of halomethylketones as pharmacological tools for the study of GSK-3beta functions and suggest a new mechanism for GSK-3beta inhibition that may be considered for further drug design.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19747834     DOI: 10.1016/j.bmc.2009.08.042

Source DB:  PubMed          Journal:  Bioorg Med Chem        ISSN: 0968-0896            Impact factor:   3.641


  7 in total

1.  High throughput screening against the peroxidase cascade of African trypanosomes identifies antiparasitic compounds that inactivate tryparedoxin.

Authors:  Florian Fueller; Britta Jehle; Kerstin Putzker; Joe D Lewis; R Luise Krauth-Siegel
Journal:  J Biol Chem       Date:  2012-01-23       Impact factor: 5.157

Review 2.  Developing irreversible inhibitors of the protein kinase cysteinome.

Authors:  Qingsong Liu; Yogesh Sabnis; Zheng Zhao; Tinghu Zhang; Sara J Buhrlage; Lyn H Jones; Nathanael S Gray
Journal:  Chem Biol       Date:  2013-02-21

3.  cAMP-guanine exchange factor protection from bile acid-induced hepatocyte apoptosis involves glycogen synthase kinase regulation of c-Jun NH2-terminal kinase.

Authors:  A Johnston; K Ponzetti; M S Anwer; C R L Webster
Journal:  Am J Physiol Gastrointest Liver Physiol       Date:  2011-05-05       Impact factor: 4.052

4.  Glycogen synthase kinase 3 inhibitors in the next horizon for Alzheimer's disease treatment.

Authors:  Ana Martinez; Carmen Gil; Daniel I Perez
Journal:  Int J Alzheimers Dis       Date:  2011-06-30

5.  GSK-3 Inhibitors: Preclinical and Clinical Focus on CNS.

Authors:  Hagit Eldar-Finkelman; Ana Martinez
Journal:  Front Mol Neurosci       Date:  2011-10-31       Impact factor: 5.639

Review 6.  Revisiting the Role of GSK3, A Modulator of Innate Immunity, in Idiopathic Inclusion Body Myositis.

Authors:  Manuela Piazzi; Alberto Bavelloni; Vittoria Cenni; Irene Faenza; William L Blalock
Journal:  Cells       Date:  2021-11-21       Impact factor: 6.600

7.  Towards discovery of new leishmanicidal scaffolds able to inhibit Leishmania GSK-3.

Authors:  Paula Martínez de Iturrate; Victor Sebastián-Pérez; Montserrat Nácher-Vázquez; Catherine S Tremper; Despina Smirlis; Julio Martín; Ana Martínez; Nuria E Campillo; Luis Rivas; Carmen Gil
Journal:  J Enzyme Inhib Med Chem       Date:  2020-12       Impact factor: 5.051

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.